Target intelligence / Profile preview

Small hydrophobic protein ectodomain, human respiratory syncytial virus (SH protein (RSV))

Target
SH protein (RSV)
Molecular classification
Viroporin, Viral ion channel, Viral membrane glycoprotein, Other
01

Overview

The **small hydrophobic (SH) protein** of respiratory syncytial virus is a minor envelope protein, distinct from the major fusion (F) and attachment (G) glycoproteins of RSV. Structurally, the SH protein contains an ectodomain, a single transmembrane α-helix, and small cytoplasmic domains. The SH protein oligomerizes to form a pentameric channel (viroporin) in membranes, increasing membrane permeability and functioning as a nonselective cation channel[3][6]. It is postulated to modulate the host immune response by inhibiting TNF-α signaling through interference with NF-κB activation[5]. Unlike the F and G proteins, the SH protein is **not essential for virus entry or replication** in vitro and is often absent or at much lower abundance in budding viral filaments[4][6]. Despite this, SH proteins are conserved among pneumoviruses and may play a role in virus pathogenicity and immune evasion. There are currently no licensed drugs specifically targeting the SH protein, but it has been explored as a potential antiviral target due to its role in membrane permeability and immune modulation[5][6]. **Note:** This entry does not refer to a host (human) receptor, but rather to a viral protein expressed on the virion surface. The "ectodomain" refers to the external portion of the SH protein exposed on the virus surface, but the SH protein functions mainly as a viroporin (ion channel) rather than as a classic attachment or entry receptor[3][5][6].

Other names
SH proteinSmall hydrophobic glycoprotein (RSV SH)RSV SH protein
02

Mechanism of action

For potential drugs: viroporin inhibition, disruption of channel activity, immune modulation

03

Biological functions

Ion channel activityModulation of membrane permeabilityInhibition of host immune response (e.g., reduces TNF-α signaling)Non-essential for virus entry and replication
04

Disease associations

Infection (RSV infection)Other
05

Safety considerations

Targeting viroporins carries concern for off-target membrane effectsSH is not essential for RSV infection or replication in vitro, so redundancy may reduce clinical target value
06

Interacting drugs

None in clinical use or advanced trials; some antiviral research focuses on the SH protein as a target but no approved drugs
07

Biomarkers

None established; SH protein function or expression not a standard biomarker

Beyond the preview

Go deeper on Small hydrophobic protein ectodomain, human respiratory syncytial virus (SH protein (RSV)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small hydrophobic protein ectodomain, human respiratory syncytial virus (SH protein (RSV)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call